24-week Safety And Efficacy Of Brelovitug Monotherapy For The Treatment Of Chronic Hepatitis D: Data From Phase 2b Of AZURE-1
Kushner, et al. Poster Presentation, EASL 2026.
Publications &
Presentations
Our commitment to rare disease innovation is reflected in our scientific research and communications. We publish our data in peer-reviewed journals and present at leading medical and scientific conferences worldwide.
By contributing rigorous evidence to the broader scientific community, we reinforce the strength of our development and commercial programs.
Featured presentations & publications
Efficacy and Safety of Volixibat, an IBAT Inhibitor, in Patients With Primary Sclerosing Cholangitis and Moderate-to-Severe Pruritus: Results of the VISTAS Trial
Levy, et al. Oral Presentation, EASL 2026.
Zilurgisertib in Patients With Fibrodysplasia Ossificans Progressiva: Interim Results From the PROGRESS Study
Pignolo, et al. Poster Presentation, ENDO 2026.
Zilurgisertib in Patients With Fibrodysplasia Ossificans Progressiva: Interim Results From the PROGRESS Study
Moran, et al. Oral Presentation, ENDO 2026.
Volixibat for the treatment of cholestatic pruritus in primary biliary cholangitis: an adaptive, randomized, placebo-controlled phase 2B trial (VANTAGE): 28-week interim results
Heneghan, et al., Presentation, EASL 2025
Latest research updates
Topic
Type
Until a relevant regulatory agency has approved a Mirum product for a specific disease or population, any scientific presentations regarding such disease or population are not to be considered instruction on the appropriate use of Mirum products or clinical candidates.